-
2024-511807-41-00
5
Hemophagocytic lymphohistiocytosis (HLH)
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2023-507010-27-00
5
Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cu
-
2023-509392-17-00
5
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-511807-41-01
5
Hemophagocytic lymphohistiocytosis (HLH)
-
2024-514243-29-01
5
This is a prospective, French, multicenter, open-label, design, strati
-
2024-515714-40-00
4
Gout adult patients
-
2024-516570-30-00
4
Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
-
2024-518310-28-00
5
Algoneurodystrophy
CRPS type 1
-
2024-518437-28-00
5
Sickle cell disease
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-519753-11-00
4
Resectable borderline pancreatic adenocarcinoma
-
2024-519894-20-01
5
Adult with an staphylococcal prosthetic joint infection treated with d
-
2025-521113-13-00
10
Early Parkinson’s Disease
-
2025-521199-80-00
4
Patients with previously untreated symptomatic chronic lymphocytic leu
-
2025-521322-14-00
4
Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation,
-
2025-522005-38-00
5
sickle cell anaemia with vaso-occlusive crisis
-
2025-522193-37-00
5
Septic arthritis
-
2025-523094-42-00
5
Hirschsprung's disease
-
2025-523683-20-00
4
Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
-
2025-524078-40-00
5
Chronic Spontaneous Urticaria
-
2025-524316-11-00
5
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-524697-42-00
5
Pleural infections
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re